Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: NUMIF )

0.0321 -0.0009 (-2.73%)
Streaming Delayed Price Updated: 3:37 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 200,953
Open 0.0335
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0330
Today's Range 0.0319 - 0.0356
52wk Range 0.0170 - 0.1550
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions
Numinus Wellness sells U.S. clinics to Stella for $3.5M, in a partnership to develop tech-driven solutions for mental health providers. 
Via Benzinga
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
Via Benzinga
Exposures Product Safety

Performance

YTD
-63.73%
-63.73%
1 Month
+60.50%
+60.50%
3 Month
+44.59%
+44.59%
6 Month
-35.80%
-35.80%
1 Year
-57.20%
-57.20%

More News

Read More
Psychedelics Co. Numinus Narrows Loss In Q3, Reports QoQ Decrease In Revenue, Gross Profit
Via Benzinga
Psychedelics-Focused Numinus Plans To Leverage This AI Technology Via New Strategic Acquisition
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
Via Benzinga
Two Top Biotechs Forge MDMA Supply Deals For Clinical Research
Via Benzinga
Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions
Via Benzinga
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
Via Benzinga
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Via Benzinga
Why Is MindMed (MNMD) Stock Up 8% Today?
Via InvestorPlace
Exposures Product Safety
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
Via Benzinga
Numinus Wellness Continues Tight Expense Management With Strategic Reviews Underway
Via Benzinga
30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond
Via Benzinga
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Via Benzinga
Numinus Reports Q4 & Full Year Fiscal 2023 Results, Including Greatly Reduced Cash Burn Rate
Via Benzinga
Psychedelics Researchers & Industry Leaders Weigh In On Groundbreaking PTSD Treatment News
Via Benzinga
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
Via Benzinga
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
Via FinancialNewsMedia
Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Small Cap Growth Virtual Investor Conference Agenda Announced for July 13th
From Virtual Investor Conferences
Via GlobeNewswire
MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University
Via Benzinga
Numinus Partners With MAPS To Conduct Phase 1 MDMA Assisted Therapy Investigational Study
Via Benzinga
Numinus' Clinical Arm To Lead Enrollment Site For MindMed's Phase 2b LSD Study
Via Benzinga
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Via Benzinga
Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.